Weight LossResearch

Cagrilintide Therapy: Complete Guide

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells that promotes satiety and slows gastric emptying. Developed by Novo Nordisk, cagrilintide is being studied both as a standalone weight-management therapy and as the amylin component of the CagriSema combination. As monotherapy in Phase 2 trials, cagrilintide 2.4 mg weekly produced approximately 10.8% mean weight loss over 26 weeks — competitive with older GLP-1 agents.

Typical cost: $300 - $650/month

What is Cagrilintide?

What Is Cagrilintide?

Cagrilintide is a long-acting synthetic analog of amylin — a pancreatic hormone co-secreted with insulin that regulates post-meal satiety, slows gastric emptying, and suppresses glucagon. Developed by Novo Nordisk, cagrilintide is engineered with a fatty acid side chain that extends its half-life to approximately 7 days, supporting once-weekly subcutaneous dosing. It is being studied both as a standalone weight-management therapy and as the amylin component of the CagriSema combination with semaglutide.

Amylin's Role in Satiety

Amylin is secreted from pancreatic beta cells alongside insulin after meals and acts primarily on receptors in the area postrema — a brainstem region outside the blood-brain barrier. Unlike GLP-1, which modulates hypothalamic appetite centers, amylin signals meal termination through a distinct pathway. The drug pramlintide (an earlier, short-acting amylin analog) established the clinical feasibility of amylin receptor agonism but required multiple daily injections. Cagrilintide's weekly dosing makes this pathway practical for chronic obesity therapy for the first time.

How Cagrilintide Works

Amylin and Calcitonin Receptor Activation

Cagrilintide binds amylin receptors — protein complexes formed by the calcitonin receptor and receptor-activity-modifying proteins (RAMPs) — in the area postrema and other brainstem regions. Activation produces meal-ending satiety signals that suppress further food intake.

Delayed Gastric Emptying

Amylin activity slows gastric emptying through a mechanism independent of GLP-1, prolonging fullness after meals.

Glucagon Suppression

Amylin suppresses post-meal glucagon secretion, contributing to improved glycemic control — particularly in type 1 and type 2 diabetes.

Pharmacokinetics

The fatty acid side chain allows cagrilintide to bind albumin in circulation, extending half-life to support once-weekly subcutaneous dosing that matches semaglutide and tirzepatide schedules.

Benefits & Uses

Clinical Benefits as Monotherapy

Weight loss: ~10.8% mean body weight reduction with cagrilintide 2.4 mg weekly over 26 weeks (Phase 2).
Preservation of lean mass: Amylin activity appears to preserve skeletal muscle better than GLP-1 monotherapy at comparable weight loss.
Glycemic improvements: Meaningful HbA1c reductions in T2D populations.
Distinct mechanism: Independent of GLP-1, allowing use in patients who cannot tolerate GLP-1 agonists or who plateau on them.
Once-weekly injection: Adherence-friendly schedule.

Role in Combination Therapy

Cagrilintide's primary commercial role is as the amylin partner in CagriSema, where it adds a second satiety pathway to semaglutide's GLP-1 activity for greater total weight loss (20.4% vs ~15%).

Clinical Evidence & Research

Phase 2 Monotherapy Trial

Enebo et al., The Lancet, 2021 — 706 adults with BMI ≥27 randomized to cagrilintide (0.3, 0.6, 1.2, 2.4, or 4.5 mg), liraglutide 3.0 mg, or placebo weekly for 26 weeks. Cagrilintide 2.4 mg produced 10.8% mean weight loss vs 3.0% placebo, with a tolerability profile favorable compared to liraglutide at comparable efficacy.

REDEFINE Program (Combination)

REDEFINE 1 and REDEFINE 2 established cagrilintide's role in the CagriSema combination, demonstrating that adding cagrilintide to semaglutide produces substantially greater weight loss than semaglutide alone.

Regulatory Status as Monotherapy

Standalone cagrilintide is not currently filed with the FDA — Novo Nordisk's regulatory strategy focuses on the CagriSema combination. Cagrilintide monotherapy may follow as a separate product if the combination is successful.

Side Effects & Safety

Common Side Effects

Nausea — most common; typically mild to moderate.
Vomiting — less common than with GLP-1 agonists at comparable weight loss.
Injection-site reactions — mild redness, itching, or swelling.
Decreased appetite — expected mechanism.
Constipation — dose-related.

GI Tolerability Advantages

In Phase 2 data, cagrilintide's GI side-effect profile was notably milder than liraglutide at comparable weight loss — a potential advantage for patients who struggle with GLP-1 tolerability.

Long-Term Safety

Human safety data beyond 26–68 weeks is limited as cagrilintide is newer to clinical development than GLP-1 agents. Pancreatitis and gallbladder risk are less established than for the GLP-1 class. Monitoring protocols parallel those for other weight-management medications.

Dosing & Administration

Clinical Trial Dosing

Cagrilintide monotherapy is administered by once-weekly subcutaneous injection. In Phase 2, doses studied included 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly, with 2.4 mg identified as the optimal efficacy/tolerability balance.

Titration

A gradual titration over 4–8 weeks is typical, starting at 0.3 mg and increasing every 2–4 weeks to 2.4 mg based on tolerability.

Administration

Subcutaneous injection in the abdomen, thigh, or upper arm. Site rotation recommended.

Access

Cagrilintide is not currently available as a standalone FDA-approved product. It is available only through clinical trial enrollment. If the CagriSema combination is approved in 2026, cagrilintide will become indirectly accessible as part of that fixed-dose combination.

Find Cagrilintide Providers Near You

Search our directory for qualified providers offering Cagrilintide therapy. Filter by location, telehealth, and more.

Browse Providers

Cagrilintide FAQ

Cagrilintide activates amylin receptors in the brainstem; semaglutide activates GLP-1 receptors in the hypothalamus. Both suppress appetite and slow gastric emptying, but through different pathways. Cagrilintide tends to cause fewer GI side effects than GLP-1 agonists and may preserve lean mass better.

At monotherapy doses studied to date, cagrilintide produces somewhat less weight loss than semaglutide (10.8% vs 14.9% in comparable trials). Its primary commercial role is as the amylin component of CagriSema, where adding it to semaglutide produces greater total weight loss than semaglutide alone.

Not currently. Cagrilintide is not available as a standalone FDA-approved product and cannot be legally compounded. It is expected to enter the US market primarily through the CagriSema fixed-dose combination.

Side-effect profile overlaps but is generally milder. Nausea and decreased appetite are common to both, but vomiting, diarrhea, and constipation tend to be less severe with amylin receptor agonism than with GLP-1 agonism at comparable weight-loss levels.

Early trial data suggest cagrilintide may preserve more lean mass during weight loss than GLP-1 monotherapy, though head-to-head body-composition data remain limited. Adequate protein and resistance training remain the strongest levers for muscle preservation on any weight-loss therapy.